10-Q: Unity Biotechnology Reports First Quarter 2024 Results, Highlights Progress on UBX1325 Clinical Trials

Unity Biotechnology reported a net loss of $5.8 million for the first quarter of 2024, while continuing to advance its lead drug candidate UBX1325 through clinical trials for diabetic macular edema.

Summary

• Unity Biotechnology, Inc. (Unity) reported a net loss of $5.8 million for the first quarter of 2024.
• The company's primary focus is on developing therapeutics to slow, halt, or reverse diseases of aging, with an initial emphasis on creating senolytic medicines to treat ophthalmologic diseases.
• Unity's lead drug candidate, UBX1325 (foselutoclax), is currently in Phase 2b clinical trials for diabetic macular edema (DME).
• The company is actively enrolling patients in the ASPIRE study, a head-to-head trial comparing UBX1325 against aflibercept, the current standard of care.
• Unity reported positive 48-week data from its Phase 2 BEHOLD study in April 2023, demonstrating that a single injection of UBX1325 led to significant and lasting improvement in vision for patients with DME.
• The company has extended the ASPIRE study from 24 to 36 weeks to assess safety, efficacy, and potentially greater durability compared to aflibercept.
• Unity expects to disclose topline results from the ASPIRE study in two data readouts: 24-week primary endpoint data in the first quarter of 2025, and 36-week long-term extension data in the second quarter of 2025.
• As of March 31, 2024, Unity had $38.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the third quarter of 2025.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's ongoing losses, limited cash runway, and the need for substantial additional financing. While the positive clinical data for UBX1325 is encouraging, the company's financial position and the early stage of its pipeline create significant uncertainty.

Positives

• UBX1325 demonstrated a favorable safety and tolerability profile in clinical trials, with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis.
• Positive 48-week data from the Phase 2 BEHOLD study showed a single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in vision lasting for the duration of the study (48 weeks).
• Approximately 53% of UBX1325-treated patients in the BEHOLD study did not require any additional injections through 48 weeks.
• Unity has successfully raised capital through various financing activities, including an inducement offer in November 2023 that generated $4.4 million in gross proceeds.

Negatives

• Unity Biotechnology reported a net loss of $5.8 million for Q1 2024 and has an accumulated deficit of $490.1 million as of March 31, 2024.
• The company has no products approved for sale and has never generated any product revenue.
• Unity will need to raise substantial additional capital to continue operations and advance its development programs.
• The company's financial condition has raised substantial doubt as to its ability to continue as a going concern.
• Unity may not be able to maintain compliance with Nasdaq listing requirements.
• The company identified a material weakness in its internal control over financial reporting related to complex security transactions.
• Unity's stock price has been volatile and may continue to be subject to fluctuations.

Risks

• Unity's core therapeutic approach based on cellular senescence is novel and unproven, exposing the company to unforeseen risks.
• The company is currently dependent on the successful development of UBX1325, which is in early stages of clinical development.
• Clinical development is lengthy, expensive, and has an uncertain outcome.
• Unity relies on third-party suppliers for manufacturing, and any disruption could materially affect the business.
• The company faces significant competition from companies with greater resources.
• Unity may be unable to obtain or maintain intellectual property protection for its products and technologies.
• The company may be subject to product liability lawsuits.
• Changes in healthcare legislation and reimbursement policies could adversely affect Unity's ability to commercialize its products.
• Unity's stock price may be volatile, and the company may not be able to maintain compliance with Nasdaq listing requirements.

Future Outlook

Unity Biotechnology expects its existing capital resources to fund its planned operating expenses into the third quarter of 2025. The company will need to raise additional capital to continue operations and advance its development programs. Topline results from the ASPIRE study are expected in two readouts: 24-week data in Q1 2025 and 36-week data in Q2 2025.

Management Comments

• Our goal with UBX1325 is to transformationally improve outcomes for patients with DME.
• These actions to prioritize our ophthalmology programs, optimize resource allocation, extend our runway, and implement cost saving measures were designed to enable us to achieve multiple key clinical data readouts for UBX1325.

Industry Context

Unity Biotechnology is engaged in the research and development of senolytic medicines, a novel therapeutic approach targeting cellular senescence to treat age-related diseases. The company's focus on ophthalmologic diseases places it within the broader ophthalmology market, where it competes with established pharmaceutical companies and other biotechnology companies developing treatments for conditions like diabetic macular edema (DME) and age-related macular degeneration (AMD).

Comparison to Industry Standards

• Unity's lead candidate, UBX1325, is being developed for DME, a major cause of vision loss in working-age adults. The current standard of care for DME involves anti-VEGF injections, such as aflibercept (Eylea) marketed by Regeneron and ranibizumab (Lucentis) marketed by Genentech/Roche.
• In the Phase 2 BEHOLD study, UBX1325 demonstrated a statistically significant improvement in BCVA compared to sham treatment at 24 and 48 weeks, with a mean change from baseline of +6.2 ETDRS letters at both timepoints. In comparison, pivotal trials of aflibercept (VISTA and VIVID) showed a mean improvement in BCVA of +10.7 and +10.5 ETDRS letters at week 24, respectively, with monthly injections.
• The ongoing Phase 2b ASPIRE study is designed to evaluate UBX1325 head-to-head against aflibercept in previously treated patients with active DME. This study will provide a direct comparison of the efficacy and durability of UBX1325 versus the standard of care.
• Other companies developing treatments for DME include Roche/Genentech, which is developing faricimab (Vabysmo), a bispecific antibody targeting both VEGF and Ang-2, and Kodiak Sciences, which is developing tarcocimab, an anti-VEGF antibody biopolymer conjugate. These treatments have shown promising results in clinical trials but require more frequent injections than what is being studied with UBX1325.
• Unity's approach of targeting senescent cells represents a novel mechanism of action in DME, distinct from the anti-VEGF therapies currently used. If successful, UBX1325 could offer a differentiated treatment option for patients with DME, potentially with a longer duration of effect and reduced treatment burden compared to existing therapies.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, risk of investment loss due to the company's financial condition and early stage of development.
• Employees: Potential impact from restructuring efforts and the need to raise additional capital.
• Patients: Potential for a new treatment option for DME if UBX1325 is successful in clinical trials and receives regulatory approval.
• Suppliers: Potential impact from the company's financial condition and reliance on third-party manufacturers.
• Creditors: Potential risk of default if the company is unable to raise additional capital or generate revenue.

Next Steps

• Continue enrolling patients in the Phase 2b ASPIRE study of UBX1325 in DME.
• Report 24-week primary endpoint data from the ASPIRE study in the first quarter of 2025.
• Report 36-week long-term extension data from the ASPIRE study in the second quarter of 2025.
• Seek additional funding to support operations and advance the development of UBX1325 and other pipeline candidates.

Key Dates

Keywords

senolytic medicines, UBX1325, foselutoclax, diabetic macular edema, DME, age-related macular degeneration, AMD, ophthalmology, clinical trials, biotechnology, aging, cellular senescence